Sorafenib + mFOLFOX for Hepatocellular Carcinoma

NCT01775501 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Cancer

Interventions

DRUG: Leucovorin
DRUG: Fluorouracil
DRUG: Oxaliplatin
DRUG: Sorafenib

Sponsor

Massachusetts General Hospital